NO20093592L - Medication for the treatment of diabetes - Google Patents
Medication for the treatment of diabetesInfo
- Publication number
- NO20093592L NO20093592L NO20093592A NO20093592A NO20093592L NO 20093592 L NO20093592 L NO 20093592L NO 20093592 A NO20093592 A NO 20093592A NO 20093592 A NO20093592 A NO 20093592A NO 20093592 L NO20093592 L NO 20093592L
- Authority
- NO
- Norway
- Prior art keywords
- medication
- diabetes
- treatment
- diabetic
- patients
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives metoder for å senke nivået av HbAIc i plasma hos diabetes-, prediabetes- og ikke-diabetes-pasienter som lider av minst en kardiovaskulær sykdom, og dette forsinker eller utsetter utviklingen eller forverringen av hyperglykemi hos slike pasienter.Methods are described for lowering plasma HbAIc levels in diabetic, prediabetic and non-diabetic patients suffering from at least one cardiovascular disease and this delays or postpones the development or worsening of hyperglycemia in such patients.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/070140 WO2008147417A1 (en) | 2007-05-31 | 2007-05-31 | Method of treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20093592L true NO20093592L (en) | 2010-01-20 |
Family
ID=38812044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20093592A NO20093592L (en) | 2007-05-31 | 2009-12-23 | Medication for the treatment of diabetes |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2152268A1 (en) |
JP (1) | JP2010528112A (en) |
KR (1) | KR20100038322A (en) |
CN (1) | CN101678017A (en) |
AU (1) | AU2007354300A1 (en) |
BR (1) | BRPI0721741A2 (en) |
CA (1) | CA2687381A1 (en) |
IL (1) | IL202002A0 (en) |
MX (1) | MX2009012957A (en) |
NO (1) | NO20093592L (en) |
WO (1) | WO2008147417A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
AU2003248558B8 (en) | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
RU2691620C1 (en) * | 2018-11-26 | 2019-06-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Method for prediction of the risk of developing ischemic heart disease in patients with type 2 diabetes mellitus combined with subclinical thyrotoxicosis |
CN110812344A (en) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
AU2003248558B8 (en) * | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
CN101098682A (en) * | 2005-01-06 | 2008-01-02 | Cv医药有限公司 | Sustained release pharmaceutical formulations comprising ranolazine |
-
2007
- 2007-05-31 BR BRPI0721741-2A patent/BRPI0721741A2/en not_active IP Right Cessation
- 2007-05-31 KR KR1020097027359A patent/KR20100038322A/en not_active Application Discontinuation
- 2007-05-31 JP JP2010510275A patent/JP2010528112A/en active Pending
- 2007-05-31 CA CA002687381A patent/CA2687381A1/en not_active Abandoned
- 2007-05-31 WO PCT/US2007/070140 patent/WO2008147417A1/en active Search and Examination
- 2007-05-31 CN CN200780053142A patent/CN101678017A/en active Pending
- 2007-05-31 AU AU2007354300A patent/AU2007354300A1/en not_active Abandoned
- 2007-05-31 EP EP07797962A patent/EP2152268A1/en not_active Withdrawn
- 2007-05-31 MX MX2009012957A patent/MX2009012957A/en not_active Application Discontinuation
-
2009
- 2009-11-09 IL IL202002A patent/IL202002A0/en unknown
- 2009-12-23 NO NO20093592A patent/NO20093592L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0721741A2 (en) | 2013-02-13 |
KR20100038322A (en) | 2010-04-14 |
WO2008147417A1 (en) | 2008-12-04 |
MX2009012957A (en) | 2010-03-03 |
CA2687381A1 (en) | 2008-12-04 |
AU2007354300A1 (en) | 2008-12-04 |
JP2010528112A (en) | 2010-08-19 |
EP2152268A1 (en) | 2010-02-17 |
CN101678017A (en) | 2010-03-24 |
IL202002A0 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhernakova et al. | Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome | |
Xue et al. | Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation | |
Graff et al. | Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment | |
Huang et al. | Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy | |
WO2010049678A3 (en) | Treatment of energy utilization diseases | |
Howes et al. | A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance | |
HK1136943A1 (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
MX2010013876A (en) | Aryl gpr119 agonists and uses thereof. | |
NO20093592L (en) | Medication for the treatment of diabetes | |
Zhang et al. | Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial | |
EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
Reynolds et al. | Individualizing warfarin therapy | |
ATE516300T1 (en) | NEUROMEDIN-U RECEPTOR AGONISTS AND THEIR USE | |
WO2007024555A3 (en) | Electronic personal health record system | |
WO2009057119A3 (en) | Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2 | |
WO2008108958A3 (en) | Benzimidazole derivatives and methods of use thereof | |
TW200833688A (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
Davies et al. | An inherited variant in the gene coding for vitamin D‐binding protein and survival from cutaneous melanoma: a B io G eno MEL study | |
Hankey et al. | Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial | |
Kreutz et al. | Cytochrome P450 3A4* 22, PPAR-α, and ARNT polymorphisms and clopidogrel response | |
Pramyothin et al. | Type 2 diabetes in children and adolescents on atypical antipsychotics | |
Gallagher et al. | Contrast-induced nephropathy in primary percutaneous coronary intervention | |
Hajjij et al. | The impact of diabetes mellitus on outcomes of endoscopic sinus surgery: a nested case‐control study | |
Maiese | Diabetic stress: new triumphs and challenges to maintain vascular longevity | |
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |